Compare Amphastar Pharmaceuticals Inc (AMPH) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Expeditors International of Wshngtn Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Expeditors International of Wshngtn Inc trades at $172.02 (market cap $22.50B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 27.2× Amphastar Pharmaceuticals Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.94% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EXPD | |
|---|---|---|
Market Cap | $826.08M | $22.50B |
Sector | Health | Industrials |
52-Week High | $30.81 | $172.02 |
52-Week Low | $16.87 | $111.37 |
Enterprise Value | $1.22B | $21.75B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
EXPD trades at $172.02, near its R1 resistance of $173, with a bullish technical outlook supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.71 surpassing the $1.33 expectation. Revenue growth remains steady, reaching $11.07B in 2025, while maintaining strong profitability with a 36.59% ROE. Recent news highlights momentum from e-commerce demand and strategic focus on supply chain management.
The stock presents growth potential driven by earnings momentum and solid fundamentals, but faces headwinds from analyst skepticism (only 12% buy ratings) and valuation concerns with a P/E of 27.79 above industry averages. Key risks include freight market volatility and geopolitical supply chain pressures. The consensus price target of $159 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
